The dawn of phage therapy. (3rd May 2019)

• Record Type: Journal Article
• Authors: Rehman, Sana; Ali, Zahid; Khan, Momna; Bostan, Nazish; Naseem, Saadia
• Is Part Of: Reviews in medical virology. Volume 29:Number 4(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-05-03
• Subjects: bacteriophages -- development -- endolysin -- therapy -- use; Medical virology -- Periodicals; Review Literature -- Periodicals; Virus Diseases -- Periodicals; Viruses -- Periodicals; 616.0194
• DOI: 10.1002/rmv.2041
• Languages: English
• ISSNs: 1052-9276

Abstract

Summary: Bacteriophages or phages, being the most abundant entities on earth, represent a potential solution to a diverse range of problems. Phages are successful antibacterial agents whose use in therapeutics was hindered by the discovery of antibiotics. Eventually, because of the development and spread of antibiotic resistance among most bacterial species, interest in phage as therapeutic entities has returned, because their noninfectious nature to humans should make them safe for human nanomedicine. This review highlights the most recent advances and progress in phage therapy and bacterial hosts against which phage research is currently being conducted with respect to food, human, and marine pathogens. Bacterial immunity against phages and tactics of phage revenge to defeat bacterial defense systems are also summarized. We have also discussed approved phage‐based products (whole phage‐based products and phage proteins) and shed light on their influence on the eukaryotic host with respect to host safety and induction of immune response against phage preparations. Moreover, creation of phages with desirable qualities and their uses in cancer treatment, vaccine production, and other therapies are also reviewed to bring together evidence from the scientific literature about the potentials and possible utility of phage and phage encoded proteins in the field of therapeutics and industrial biotechnology.